Deutsch English Français

Contact

EP1720540

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1720540

EP1720540 - SATRAPLATIN FOR TREATING RESISTANT OR REFRACTORY TUMORS [Right-click to bookmark this link]
Former [2006/46]	METHODS FOR TREATING RESISTANT OR REFRACTORY TUMORS
	[2007/34]
Status	No opposition filed within time limit Status updated on 17.04.2009 Database last updated on 06.07.2024
Most recent event Tooltip	17.04.2009	No opposition filed within time limit	published on 20.05.2009 [2009/21]
Applicant(s)	For all designated states GPC Biotech AG Fraunhoferstrasse 20 82152 Martinsried / DE
	[2006/46]
Inventor(s)	01 / CALIGIURI, Maureen 159 Pine Ridge Rd. Reading, MA 01867 / US
	02 / WOSIKOWSKI-BUTERS, Katja Minervaweg 6 85586 Poing / DE
	03 / CASAZZA, Anna Maria 40 Canady Lane Madison, CT 06443 / US
	[2008/24]
Former [2008/21]	01 / CALIGIURI, Maureen 159 Pine Ridge Rd. Reading, MA 01867 / US
	02 / WOSIKOWSKI-BUTERS, Katja Minervaweg 6 85586 Poing / DE
	03 / CASAZZA, Anne Maria 40 Canady Lane Madison, CT 06443 / US
Former [2006/46]	01 / CALIGIURI, Maureen 159 Pine Ridge Rd. Reading, MA 01867 / US
	02 / WOSIKOWSKI-BUTERS, Katja Seerosenstrasse 3 85586 Poing / DE
	03 / CASAZZA, Anne Maria 40 Canady Lane Madison, CT 06443 / US
Representative(s)	Dörries, Hans Ulrich df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München / DE
	[N/P]
Former [2006/46]	Dörries, Hans Ulrich Dörries, Frank-Molnia & Pohlman, Triftstrasse 13 80538 München / DE
Application number, filing date	05715410.6	18.02.2005
	[2006/46]
	WO2005EP01733
Priority number, date	US20040546097P	18.02.2004 Original published format: US 546097 P
	[2006/46]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2005077385
	Date:	25.08.2005
	Language:	EN
	[2005/34]
	Type:	A2 Application without search report
	No.:	EP1720540
	Date:	15.11.2006
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 25.08.2005 takes the place of the publication of the European patent application.
	[2006/46]
	Type:	B1 Patent specification
	No.:	EP1720540
	Date:	11.06.2008
	Language:	EN
	[2008/24]
Search report(s)	International search report - published on:	EP	10.11.2005
Classification	IPC:	A61K31/282, A61P35/00, A61K33/24	[2006/46]
	CPC:	A61K45/06 (EP,US); A61K31/282 (EP,US); A61K31/555 (EP,US); A61K33/243 (EP,US); A61P35/00 (EP)
	C-Set:	A61K31/282, A61K2300/00 (EP,US); A61K31/555, A61K2300/00 (US,EP); A61K33/24, A61K2300/00 (US,EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/46]
Extension states	AL	18.09.2006
	BA	18.09.2006
	HR	18.09.2006
	LV	18.09.2006
	MK	18.09.2006
	YU	18.09.2006
Title	German:	SATRAPLATIN ZUR BEHANDLUNG VON RESISTENTEN ODER REFRKATÄREN TUMOREN	[2007/34]
	English:	SATRAPLATIN FOR TREATING RESISTANT OR REFRACTORY TUMORS	[2007/34]
	French:	SATRAPLATIN DANS LE TRAITEMENT DE TUMEURS RESISTANTES OU REFRACTAIRES	[2007/34]
	Former [2006/46]	VERFAHREN ZUR BEHANDLUNG VON RESISTENTEN ODER REFRKATÄREN TUMOREN
	Former [2006/46]	METHODS FOR TREATING RESISTANT OR REFRACTORY TUMORS
	Former [2006/46]	TRAITEMENTS DE TUMEURS RESISTANTES OU REFRACTAIRES
Entry into regional phase	18.09.2006	National basic fee paid
	18.09.2006	Designation fee(s) paid
	18.09.2006	Examination fee paid
Examination procedure	18.09.2006	Examination requested [2006/46]
	02.11.2006	Amendment by applicant (claims and/or description)
	25.04.2007	Despatch of a communication from the examining division (Time limit: M02)
	05.07.2007	Reply to a communication from the examining division
	19.11.2007	Communication of intention to grant the patent
	19.03.2008	Fee for grant paid
	19.03.2008	Fee for publishing/printing paid
Divisional application(s)	EP08102968.8 / EP1967189
Opposition(s)	12.03.2009	No opposition filed within time limit [2009/21]
Fees paid	Renewal fee
	13.02.2007	Renewal fee patent year 03
	14.02.2008	Renewal fee patent year 04
	28.03.2008	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]US6025473 (DEELEY ROGER G [CA], et al) [X] 1-38 * column 6, lines 20-24 *;
		[PX]WO2004105761 (PHARMA MAR SAU [ES], et al) [PX] 1-38 * the whole document *;
		[PX] - PLASENCIA CARMEN ET AL, "Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines", INVESTIGATIONAL NEW DRUGS, (200411), vol. 22, no. 4, ISSN 0167-6997, pages 399 - 409, XP002330769 [PX] 1-38 * abstract * DOI: http://dx.doi.org/10.1023/B:DRUG.0000036682.99818.71
		[X] - SOULIE P ET AL, "Oxaliplatin/cisplatin (L-OHP/CDDP) Combination in Heavily Pretreated Ovarian Cancer", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (199708), vol. 33, no. 9, ISSN 0959-8049, pages 1400 - 1406, XP004284356 [X] 1-38 * abstract * DOI: http://dx.doi.org/10.1016/S0959-8049(97)00122-6
		[X] - ZELEK L ET AL, "Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 15 MAY 2002, (20020515), vol. 20, no. 10, ISSN 0732-183X, pages 2551 - 2558, XP002330770 [X] 1-38 * abstract * DOI: http://dx.doi.org/10.1200/JCO.2002.06.164
		[X] - SHARP S Y ET AL, "Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines", BRITISH JOURNAL OF CANCER, (199807), vol. 78, no. 2, ISSN 0007-0920, pages 175 - 180, XP009048459 [X] 1-38 * abstract *
		[X] - MEDINA-GUNDRUM LETICIA ET AL, "AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients.", ANTI-CANCER DRUGS, (200304), vol. 14, no. 4, ISSN 0959-4973, pages 275 - 280, XP009048496 [X] 1-38 * abstract * DOI: http://dx.doi.org/10.1097/00001813-200304000-00004
		[X] - SMITH D C, "Chemotherapy for hormone refractory prostate cancer", UROLOGIC CLINICS OF NORTH AMERICA 1999 UNITED STATES, (1999), vol. 26, no. 2, ISSN 0094-0143, pages 323 - 331, XP009048474 [X] 1-38 * page 329, column 1, paragraph 2 * DOI: http://dx.doi.org/10.1016/S0094-0143(05)70072-0
	by applicant	- E. K. ROWINSKY; R. C. DONEHOWER, PHARMACOLOGY AND THERAPEUTICS, (1991), vol. 52, pages 35 - 84
		- J BIOL CHEM, (1997), vol. 272, pages 1711 - 17124
		- VICKERS ET AL., MOL ENDOCRINOLOGY, (1989), vol. 3, no. 1, pages 157 - 164
		- KAPOOR ET AL., ONCOLOGY RESEARCH, (1995), vol. 7, pages 83 - 95
		- ONCOGENE, (2004), vol. 23, page 474482
		- CLIN CANCER RES, (2003), vol. 9, pages 2778 - 2785
		- CANCER RES, (2001), vol. 61, no. 37, pages 6034 - 6
		- CANCER RES, (1994), vol. 54, pages 152 - 158
		- INT J CANCER, (1997), vol. 71, pages 35 - 41

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p